Table 1.

Baseline, nadir, and maximal cutaneous vascular conductance

	Baseline CVC, %max			Nadir CVC, %max	Maximal CVC, mV/MAP·100
	Protocol 1	Protocol 2	Protocol 3	Protocol 2	Protocol 1	Protocol 2	Protocol 3
Control	6.9 ± 2.1	8.7 ± 1.4	7.7 ± 1.1	24.4 ± 3.3	192.6 ± 7.9	220 ± 20	294 ± 37
TEA		5.5 ± 0.9*	3.9 ± 0.4*	11.3 ± 2.1*		213 ± 18	351 ± 43
L-NAME		4.9 ± 0.6*	5.9 ± 0.7*	8.1 ± 1.2*		209 ± 23	269 ± 28
TEA+L-NAME		3.3 ± 0.4*	4.4 ± 1.0*	5.0 ± 0.6*†		200 ± 16	285 ± 33

Drugs include tetraethylammonium (TEA) and nitro-L-arginine methyl ester (L-NAME); CVC, cutaneous vascular conductance. Data are means ± SE. Data for protocol 1 are pooled data across all nine combinations of rates of local heating target temperatures.

^*P < 0.05 compared with the Control site within each protocol;

^†P < 0.05 compared with the TEA site within each Protocol.